Recombinant Human Interferon lambda-1 protein (IFNL1) (Active)

In Stock
Code CSB-AP002811HU
Abbreviation Recombinant Human IFNL1 protein (Active)
MSDS
Size $142
Order now
Image
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Purity
>97% as determined by SDS-PAGE.
Endotoxin
Less than 1.0 EU/μg as determined by LAL method.
Activity
Fully biologically active when compared to standard. The ED50 as determined by an anti-viral assay using human HepG2 cells infected with encephalomyocarditis is less than 5 ng/ml, corresponding to a specific activity of >2.0x105 IU/mg.
Target Names
Uniprot No.
Research Area
Immunology
Alternative Names
IFN-lambda-1, Interleukin-29, IL-29
Species
Homo sapiens (Human)
Source
E.coli
Expression Region
20-200aa
Complete Sequence
GPVPTSKPTT TGKGCHIGRF KSLSPQELAS FKKARDALEE SLKLKNWSCS SPVFPGNWDL RLLQVRERPV ALEAELALTL KVLEAAAGPA LEDVLDQPLH TLHHILSQLQ ACIQPQPTAG PRPRGRLHHW LHRLQEAPKK ESAGCLEASV TFNLFRLLTR DLKYVADGNL CLRTSTHPES T
Mol. Weight
19.8 kDa
Protein Length
Full Length of Mature Protein
Tag Info
Tag-Free
Form
Lyophilized powder
Buffer
Lyophilized from a 0.2 μm filtered PBS, pH 7.4
Reconstitution
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. Our default final concentration of glycerol is 50%. Customers could use it as reference.
Troubleshooting and FAQs
Storage Condition
Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
Shelf Life
The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
Lead Time
5-10 business days
Notes
Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
Datasheet & COA
Please contact us to get it.
Description

Recombinant Human Interferon lambda-1 protein (IFNL1) is produced in E. coli and contains the complete mature protein sequence from amino acids 20-200. This tag-free protein achieves purity levels above 97% based on SDS-PAGE analysis. The protein shows full biological activity, with an ED50 below 5 ng/ml when tested in anti-viral assays using human HepG2 cells. Endotoxin levels remain under 1.0 EU/µg, which appears to make it well-suited for high-quality research work.

Interferon lambda-1 belongs to the type III interferon family and seems to play an important role in how the immune system responds to viral infections. What makes it particularly interesting is that it signals through a receptor complex that's different from type I and II interferons. This pathway primarily targets epithelial cells. Scientists are drawn to this protein because of its involvement in antiviral defense and its potential therapeutic uses - it may be able to modulate immune responses without causing the inflammatory side effects that often come with other interferons.

Potential Applications

Note: The applications listed below are based on what we know about this protein's biological functions, published research, and experience from experts in the field. However, we haven't fully tested all of these applications ourselves yet. We'd recommend running some preliminary tests first to make sure they work for your specific research goals.

1. Antiviral Activity Screening and Mechanism Studies

This recombinant IFNL1 protein works well for investigating how interferon lambda-1 fights various viral pathogens in controlled laboratory conditions. With its proven biological activity (ED50 less than 5 ng/ml in anti-viral tests), researchers can map out dose-response relationships across different virus-cell model systems. The high purity (>97%) and minimal endotoxin contamination make it possible to study direct antiviral effects without getting confused by inflammatory responses. Research like this could help clarify interferon lambda's role in innate immunity and how its antiviral capabilities differ from type I interferons.

2. Interferon Lambda Receptor Binding and Signaling Studies

The biologically active IFNL1 protein serves as a useful ligand for exploring how interferon lambda receptors (IFNLR1/IL10RB) bind and trigger downstream signaling pathways. Scientists can incorporate this protein into binding competition assays, receptor internalization experiments, and JAK-STAT pathway studies using various cell lines. Since the protein lacks fusion tags, it's less likely to interfere with receptor binding experiments. This type of work may advance our understanding of interferon lambda receptor biology and why different tissues respond differently.

3. Comparative Interferon Response Analysis

This recombinant IFNL1 proves useful for comparative studies that examine how type III interferons affect gene expression and cellular responses differently than type I interferons. The high specific activity (>2.0 × 10⁵ IU/mg) allows for precise dosing in transcriptomic and proteomic studies across different cell types. Scientists can explore how various tissues respond to interferon, particularly in epithelial cells where interferon lambda responses tend to be most prominent. Studies like these might help clarify the distinct biological roles that different interferon classes play.

4. Antibody Development and Validation

The high-purity, tag-free IFNL1 protein works well as both an immunogen and standard for developing and testing anti-IFNL1 antibodies for research purposes. Its biological activity can help validate whether neutralizing antibodies actually work in the established HepG2 antiviral assay system. Low endotoxin content helps ensure that immune responses target the IFNL1 protein specifically rather than bacterial contaminants. This application supports the creation of research tools for studying how interferon lambda is naturally expressed and functions.

5. Cell-Based Assay Development and Standardization

This biologically active IFNL1 protein can serve as a reference standard for creating and validating new cell-based assays that measure interferon lambda activity or how well cells respond to it. The established ED50 value provides a useful benchmark for assay sensitivity and helps ensure reproducibility between different laboratories. Researchers can use this protein to fine-tune assay conditions, test new reporter cell lines, or build high-throughput screening platforms for interferon lambda research. The consistent biological activity appears to support standardization efforts across interferon lambda research methods.

Customer Reviews and Q&A

 Customer Reviews
Average Rating:
5.0 - 1 reviews

Submit a Review here

Applications : /

Review: Recombinant Human Interferon Lambda-1 (IFNL1) protein was brought from CUSABIO (CUSABIO, Houston, TX, USA).

By Anonymous

Target Background

Function
Cytokine with antiviral, antitumour and immunomodulatory activities. Plays a critical role in the antiviral host defense, predominantly in the epithelial tissues. Acts as a ligand for the heterodimeric class II cytokine receptor composed of IL10RB and IFNLR1, and receptor engagement leads to the activation of the JAK/STAT signaling pathway resulting in the expression of IFN-stimulated genes (ISG), which mediate the antiviral state. Has a restricted receptor distribution and therefore restricted targets: is primarily active in epithelial cells and this cell type-selective action is because of the epithelial cell-specific expression of its receptor IFNLR1. Exerts an immunomodulatory effect by up-regulating MHC class I antigen expression.
Gene References into Functions
  1. SOCS2 impairs IFN/JAK/STAT signaling through reducing the stability of tyrosine kinase 2 (TYK2), downregulating the expression of type I and III IFN receptors, attenuating the phosphorylation and nucleus translocation of STAT1. PMID: 28496097
  2. In conclusion, IL-29 enhanced CXCL10 production in human oral epithelial cells via the p38 MAPK, STAT3, and NF-kappaB pathways, which might control Th1-cell accumulation in periodontal lesions and be involved in pathological processes in periodontal disease. PMID: 28753407
  3. The DNA binding domain of Ku70 was essential for formation of the Ku70-STING complex. Knocking down STING in primary human macrophages inhibited their ability to produce IFN-lambda1 in response to transfection with DNA or infection with the DNA virus HSV-2 (herpes simplex virus-2). Together, these data suggest that STING mediates the Ku70-mediated IFN-lambda1 innate immune response to exogenous DNA or DNA virus infection. PMID: 28720717
  4. The review focuses on the value of the type I and III interferon subtypes (alphas, beta and lambdas) as therapeutics for prevention and treatment of viral infections (influenza, herpes, human immunodeficiency virus and hepatitis viruses). PMID: 27544015
  5. Interferon lambda1/IL-29 and inorganic polyphosphate are novel regulators of neutrophil-driven thromboinflammation. PMID: 28678391
  6. IFN-lambda1 may play an important role in anti-respiratory syncytial virus infection. PMID: 28606236
  7. Ebola virus VP24, in addition of inhibiting IFN-induced antiviral responses, was found to efficiently inhibit type III IFN-lambda1 gene expression. PMID: 28595092
  8. STAT2 recruits USP18 to the type I IFN receptor subunit IFNAR2 via its constitutive membrane-distal STAT2-binding site. PMID: 28165510
  9. IFN-lambda1 is likely to play a role in the pathogenesis of CSU. Blocking IFN-lambda1 production may help to reduce the accumulation of inflammatory cells in the involved CSU skin. PMID: 27445435
  10. IL-29 stimulates inflammation and cartilage degradation by OA FLS, indicating that this cytokine is likely involved in the pathogenesis of OA. PMID: 27433031
  11. IL-29 is a potential biomarker for disease activity in anti-cyclic citrullinated peptide-antibodies positive rheumatoid arthritis patients. PMID: 28154345
  12. this study shows that serum levels of IL-29 play a role in the pathogenesis of Hashimoto's thyroiditis in Turkey PMID: 27617784
  13. serum levels of IL-32 and TNF-alpha may be diagnostic markers, and serum IL-29 levels may be associated with good prognosis in patients with gastric cancer PMID: 26219901
  14. Serum levels of IL-29 and IFN-gamma are predictive of relapse outcomes after hepatitis C treatment. PMID: 26342113
  15. IL-29 selectively induces CXCR3A-binding chemokines (CXCL9, CXCL10, CXCL11) in skin cells. Murine IL-29 counterpart induces skin T-cell infiltration and inflammation in mice. PMID: 26612594
  16. activation of TLR7 upregulated the expression levels of IFN-lambda1 and MMP-9 were increased by ~3 fold, whereas other genes (p53, PTEN, TIMP-1) were upregulated by ~2 fold, and VEGF was marginally upregulated after 10 min. PMID: 26718740
  17. IL-29 directly induces RANKL expression in rheumatoid arthritis-fibroblasts like synoviocytes via MAPK signaling pathway. PMID: 26420479
  18. showed that silencing IFN-lambda1 in T/T cell line reduced basal IFN-stimulated gene expression and improved antiviral activity PMID: 26896692
  19. IFN-lambda-1 and interferon-gamma levels in systemic sclerosis patients were significantly higher than those in healthy individuals. PMID: 26057401
  20. this study failed to prove any significant association between polymorphisms in IL29 gene rs30461 or IL10 gene (-1082, -819 and -592) or cytokine haplotype and either response to therapy or severity of HCV infection in children. PMID: 25936570
  21. IL-29 can aggravate LPS/TLR4-mediated inflammation. PMID: 26278073
  22. NS of severe fever with thrombocytopenia syndrome virus inhibited the activity of IFN-alpha1, IFN-beta, IFN-lambda1 and IFN-lambda2 through inhibition of STAT1 phosphorylation. PMID: 26353965
  23. the role of IFN-lambda in IDO regulation was investigated after influenza infection of respiratory epithelial cells. PMID: 25756191
  24. Data suggest that naturally occurring iDVGs (immunostimulatory defective viral genomes) trigger robust host antiviral/innate immunity responses including/requiring up-regulation of IFNL1 and IFNB1 (interferon beta 1) in respiratory mucosa. PMID: 26336095
  25. there seems to be an inverse link between IFN-lambda and the severity of allergic asthma and allergic asthma exacerbations. PMID: 25592858
  26. Studies indicate that the type III interferons (IFNs) or IFN-lambdas consists of four members: IFN-lambda1 (IL-29), IFN-lambda2 (IL28A), IFN-lambda3 (IL-28B) and IFN-lambda4. PMID: 26194286
  27. Increased quantity of IL-29 in GCF and plasma of subjects with periodontitis suggests a role in pathogenesis of periodontitis and the SNP (rs30461) is not related to susceptibility to periodontitis in this population of Indian individuals. PMID: 25255471
  28. Severity of rhinovirus-induced asthma symptoms is inversely related to resolution IFNL1 expression. PMID: 25784275
  29. IL-29 is dysregulated in patients with rheumatoid arthritis (RA), which may contribute to the RA pathogenesis via inducing the production of proinflammatory cytokines, chemokines or matrix metalloproteinases in synovial fibroblasts. PMID: 23078630
  30. intranasal delivery of adenovirus expressing protein suppresses allergic asthma in a murine model PMID: 24819718
  31. IFN-lambda1-mediated IL-12 production in macrophages induces IFN-gamma production in human NK cells. PMID: 25316442
  32. data suggest that the p38alpha MAPK pathway is linked with RLR signaling pathways and regulates the expression of early IFN genes after RNA stimulation cooperatively with IRF3 and NF-kappaB to induce antiviral responses further PMID: 25473098
  33. Interferon lambda 1 induces antiviral response to herpes simplex virus 1 infection. PMID: 25518713
  34. These results show that type III interferons (IFN-lambdas) play a critical protective role in human metapneumovirus infection. PMID: 25355870
  35. Results showed no association between genotypes and alleles of IL28A, IL28B or IL29 polymorphisms and Hepatitis C virus infection. PMID: 24269996
  36. This study is the first to show the activation of a type III interferon response in low-risk human papillomavirus positive cervical cells and suggests that the lack of this response may be related to lesion progression. PMID: 24510368
  37. our data suggest that human but not mouse hepatocytes are responsive to IFN-lambda in vivo. PMID: 24498220
  38. protein expression is inhibited by hepatitis C virus PMID: 23529855
  39. IFNL1 expression in the human colon is transcriptionally regulated by ZEB-1, BLIMP-1, and NF-kappaB p50 and p65. PMID: 24140069
  40. These data suggest that T(Helper)17 cell-derived IL-29, which is absent in atopic dermatitis, mediates the robust antiviral state on psoriatic skin, and demonstrate a new function of T(H)17 cells. PMID: 24068736
  41. HBV infection upregulates IL-27 expression, which, in turn, stimulates IFN-lambda1 production. PMID: 24337382
  42. Interferon regulatory factor (IRF)-3 and -7 are the key transcriptional factors for the induction of IL-28A and IL-28B genes, whereas NF-kappaB is an additional requirement for the induction of the IL-29 gene. PMID: 24385435
  43. IL-32 levels during viral infection mediate antiviral effects by stimulating the expression of IFN-lambda1. PMID: 23729669
  44. IFN-lambdas can also directly affect T cells through inhibition of the T helper 2 cell (Th2) responses. IFN-lambdas have varying immunomodulatory functions under different physiological conditions PMID: 23207147
  45. RA patients that presented knee joint involvement displayed higher serum IFN-lambda1 than patients without knee joint involvement, suggesting that abnormally elevated IFN-lambda1 levels in RA can associate with knee joint disease. PMID: 23039206
  46. The viral infection induced both IFN-lambda1 promoter activity and that of the 3'-untranslated region (UTR), indicating that IFN-lambda1 expression is also regulated at the post-transcriptional level. PMID: 23150165
  47. IL-29 can regulate expression of protease activated receptors and tryptase- and trypsin-induced IL-4 production in mast cells. PMID: 23218741
  48. These data support a model of coordinated cell- and ligand-specific expression of types I and III interferon. PMID: 22249201
  49. After non-surgical periodontal therapy, IL-29 levels increased both in chronic and aggressive periodontitis patients. PMID: 23151616
  50. IFN-alpha and IFN-lambda signal through distinct receptors, they induce expression of a common set of ISGs in hepatocytes. However, unlike IFN-alpha, IFN-lambda1 did not induce STAT activation or ISG expression by purified lymphocytes or monocytes PMID: 23258595

Show More

Hide All

Subcellular Location
Secreted.
Protein Families
Lambda interferon family
Database Links

HGNC: 18363

OMIM: 607403

KEGG: hsa:282618

STRING: 9606.ENSP00000329991

UniGene: Hs.406745

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2025 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*